Previous 10 | Next 10 |
Radnor, Pennsylvania--(Newsfile Corp. - August 31, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed against Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis") on behalf of those who purchased or acquired Annov...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips There are circumstances crueler than death, and Alzheimer’s disease may be one of them. For patients and their families, suffering from and witnessing the deterioration of mental and physical faculties is utterly dev...
Investing in pre-product biotech companies often feels like gambling. Financial analysis might not deliver meaningful conclusions for businesses without revenue, and the risks inherent to the drug development process are often discouraging. But buying biotech stocks doesn't need to actual...
Presentation will highlight positive biomarker data that corroborates the positive efficacy data from two Phase 2 studies of ANVS401 Dr. Maccecchini to present virtually, Thursday, August 26, at 1:00 p.m. ET Berwyn, Pennsylvania--(Newsfile Corp. - August 25, 2021) - Annovis, Bio, Inc. (N...
It has been tough for ANVS' investors since July 28, when the company presented phase 2a Alzheimer's & Parkinson's results at the Alzheimer's Association International Conference (AAIC). The stock had gone from $109.44 on July 28 to $37.10 on Aug 20, a >66% drop, responding to ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips If market performance represented the only reflection of a biotechnology company’s worth, then Cassava Sciences (NASDAQ: SAVA ) would be a mesmerizing deal. Since the start of the year, SAVA stock has gained a ...
Boston, Massachusetts--(Newsfile Corp. - August 18, 2021) - Block & Leviton announces that a class action lawsuit has been filed against Annovis Bio Inc. (NYSE American: ANVS) and certain of its officers for securities law violations. Investors who purchased shares between May 21, 2021 and...
40 additional patients completed treatment On track to disclose final safety and efficacy data in early Fall Toxic cascade markers expected to be disclosed in two to three months Planning to present all Phase 2a data to the FDA in Q4 2021 and begin Phase 3 in Q1 2022 Berwyn, Penns...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Millions of Americans are struggling with Alzheimer’s, according to the Alzheimer’s Association . The disease often has a slow progression, lasting years or even decades, and it’s one of the lead...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips After the U.S. Food and Drug Administration approved Biogen (NASDAQ: BIIB ) Alzheimer’s drug, it fueled an uptrend for Cassava Sciences (NASDAQ: SAVA ). But in late July, buying euphoria capitulated. SAVA...
News, Short Squeeze, Breakout and More Instantly...
Annovis Bio (NYSE: ANVS) , a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), today announced the receipt of U.S. Patent No. 12,042,482. The patent ...
MALVERN, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’...
The new executive team includes Mark White, Alexander Morin, Hilda Maibach, and Blake Jensen These additions are pivotal as the company makes strides toward bringing flagship drug candidate buntanetap closer to New Drug Application (“NDA”) status and to market Annovis Bio (NYS...